Do you have lupus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM)? You may be eligible for a new CAR-T therapy conducted at University of North Carolina at Chapel Hill. Please reach out to learn more about this new innovative treatment.

Are you a woman with a history of breast cancer (Stage 0-III)? Do you identify as Black/African-American? Do you struggle with fear or worry that your cancer may return? If you are a breast cancer survivor that identifies as Black/African-American, you may be eligible to participate in the FoRtitude Interview Study. Compensation provided.

The purpose of this study is to test the safety and eff ectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan; or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating your type of cancer. Additional information collected from this study may also help inform the future use of these drugs.

Do you have metastatic or incurable, recurrent head and neck cancer? If so, you may be able to participate in a research study to find out if a new investigational drug, in combination with pembrolizumab, can help people with advanced head and neck cancer.

In this study, we want to find out if a medicine called Olaparib works as well as the usual treatment for ovarian cancer. We also want to see if this medicine can help stop the cancer from growing or coming back.

The purpose of this research study is to look at a program that includes expert review of your tumor genetic test results. We want to see if this program can help your doctor identify better treatments or suitable clinical trials for your cancer. This is a hybrid decentralized study where some if not all assessments may be performed remotely or close to your home.

This is a study of an investigational drug called YL201 as a possible treatment for advanced solid tumors. YL201 is thought to work by interrupting DNA replication in cancer cells, via focused delivery of the cytotoxic agent to the cancer cell. YL201 has shown some anti-cancer effects against cancer cells in the laboratory and in experimental animals. The main purpose of this study is to learn how safe the study drug and how well the study drug works.

Is your child between the ages of 8 and 11? Was your child assigned female sex at birth? If so, you may be able to take part in a study to see how social experiences and puberty can affect the mental health of preteen girls. We want to help improve youth mental health support. Compensation provided.

This research is being done in participants who have Hepatocellular Carcinoma (HCC), also referred to as Liver Cancer, to evaluate how 3 drugs work in combination, and which dose is the best to treat your disease. The 3 drugs are casdozokitug (casdozo-key-tug), toripalimab (tor-i-pal-i- mab) and bevacizumab (bev-uh-siz-oo-mab). Toripalimab and bevacizumab have been approved by the Food and Drug Administration (FDA) to treat other cancers, but not Liver cancer. Casdozokitug has not been approved by the FDA to treat any cancers.